



Triazole Antifungal Susceptibility Patterns among *Aspergillus* Species in Québec, Canada

Matthew P. Cheng^{a,b,c} Alexander Lawandi^d Todd C. Lee^{d,e} Philippe J. Dufresne^f Danila Seidel^{g,h} Paul E. Verweijⁱ
Oliver A. Cornely^{g,h,j} Donald C. Sheppard^{d,e,k}

^aDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA

^bDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

^cHarvard Medical School, Boston, Massachusetts, USA

^dDivision of Infectious Diseases, Department of Medicine, McGill University, Montreal, Canada

^eMcGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Canada

^fInstitut National de Santé Publique du Québec, Laboratoire de Santé Publique du Québec, Montreal, Québec, Canada

^gDepartment I of Internal Medicine, ECMM Center of Excellence for Medical Mycology, German Center for Infection Research, partner site Bonn-Cologne (DZIF), University Hospital of Cologne, Cologne, Germany

^hCologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany

ⁱCenter of Expertise in Mycology Radboudumc/CWZ, Nijmegen, the Netherlands

^jClinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany

^kDepartment of Microbiology and Immunology, McGill University, Montreal, Canada

KEYWORDS *Aspergillus*, antifungal susceptibility testing, itraconazole, posaconazole, voriconazole

Invasive aspergillosis (IA) is an important cause of morbidity and mortality among immunocompromised patients (1–3), with over 500 patients developing IA in Canada each year (4). The overall mortality rate of IA is approximately 25% (5, 6) but increases to over 60% in the setting of infection with azole-resistant *Aspergillus fumigatus* (ARAF) (7–9). Given the spread of ARAF to countries in Europe (10), Asia (11, 12), Africa, the Middle East, and the Americas (13), we sought to determine the prevalence of azole resistance among *Aspergillus* isolates in the province of Québec, Canada.

We performed antimicrobial susceptibility testing on all *Aspergillus* species isolated from sterile sites and respiratory specimens that were processed at the McGill University Health Centre (MUHC) between March 2018 and December 2018. The MUHC is a university-affiliated tertiary-care hospital in Montreal that serves as the central mycology laboratory for 10 hospitals and a population of 1.8 million in the province of Québec.

Clinical isolates of *Aspergillus* were identified to the species level by conventional microscopy techniques. For a given isolate, sporulating colonies were picked and subcultured on VIPcheck plates (Mediaproducts BV, the Netherlands) and incubated per the manufacturer's instructions. The VIPcheck plate has a sensitivity of 98% and a specificity of 93% for detecting azole resistance in *Aspergillus* species (14). Briefly, a moist, sterile swab collected conidia from the *Aspergillus* colony. A suspension with a 0.5 to 2 McFarland standard was then created in sterile water. All 4 wells of the VIPcheck plate were inoculated with a single drop of the suspension. Finally, the plate was incubated and read after 24 and 48 h. Growth in any well except the control well indicated the possibility of an azole-resistant isolate. Isolates with positive screening results were sent to the Laboratoire de Santé Publique du Québec (LSPQ; the provincial reference center) for molecular identification (by sequencing of internal transcribed spacer [ITS] and BenA regions) and antifungal susceptibility confirmatory testing by broth microdilution per the Clinical and Laboratory Standards Institute method (15, 16). Epidemiological cutoff values (ECV) were used to infer antifungal susceptibility (17).

Citation Cheng MP, Lawandi A, Lee TC, Dufresne PJ, Seidel D, Verweij PE, Cornely OA, Sheppard DC. 2019. Triazole antifungal susceptibility patterns among *Aspergillus* species in Québec, Canada. *J Clin Microbiol* 57:e00404-19. <https://doi.org/10.1128/JCM.00404-19>.

Editor Geoffrey A. Land, Carter BloodCare & Baylor University Medical Center

Copyright © 2019 American Society for Microbiology. All Rights Reserved.

Address correspondence to Matthew P. Cheng, mcheng@bwh.harvard.edu.

Accepted manuscript posted online 27 March 2019

Published 24 May 2019

TABLE 1 Antifungal susceptibility testing results with VIPcheck plates

Antifungal agent	<i>A. fumigatus</i> (n = 86)	<i>A. flavus</i> (n = 12)	<i>A. niger</i> (n = 5)	<i>A. versicolor</i> (n = 4)	<i>A. glaucus</i> (n = 2)	<i>Aspergillus calidoustus</i> (n = 2)	Other species (n = 2) ^a
Itraconazole (no. [%]) ^b	0 (0)	0 (0)	0 (0)	0 (0)	1 (50)	0 (0)	0 (0)
Voriconazole (no. [%])	0 (0)	0 (0)	0 (0)	0 (0)	1 (50)	0 (0)	0 (0)
Posaconazole (no. [%])	0 (0)	0 (0)	0 (0)	0 (0)	1 (50)	0 (0)	0 (0)
Any azole (no. [%])	0 (0)	0 (0)	0 (0)	0 (0)	1 (50)	0 (0)	0 (0)

^aThe other species included *Aspergillus terreus* and *Aspergillus nidulans*.

^bValues refer to the number and percentage of isolates that had a positive screening test with VIPcheck plates.

In total, 113 isolates were received from 5 different hospital centers across the province of Québec. The complete list of species and the results of antifungal susceptibility testing are presented in Table 1. The most common species identified were *Aspergillus fumigatus* (n = 86; 76.1%) followed by *Aspergillus flavus* (n = 12; 10.6%), *Aspergillus niger* (n = 5; 4.4%), and *Aspergillus versicolor* (n = 4; 3.5%). Only a single isolate (0.8% of total tested) of *Aspergillus glaucus* screened positive for azole nonsusceptibility in the VIPcheck plate. This isolate had MICs to itraconazole, voriconazole, and posaconazole of 0.25 mg/liter, 0.5 mg/liter, and 0.12 mg/liter, respectively. While there are no defined ECV for *A. glaucus*, the values are below the ECV for other *Aspergillus* species (17) and the isolate was thus presumed susceptible. The prevalence of azole resistance in our population is estimated at 0% (95% confidence interval [CI], 0 to 3.2%).

While patients with IA treated with an azole may require changes in therapy due to a lack of clinical efficacy, these cases can often be successfully treated with a different azole antifungal (18). Our data suggest that microbiologically confirmed azole resistance is rare in the province of Québec. Therefore, antifungal resistance to triazole antifungals is unlikely a significant contributor to clinical failure in patients with IA in our geographic area, and other factors, including host immune status, antifungal pharmacokinetics, and incorrect diagnosis, should be considered first.

Our results must be interpreted in the context of the study characteristics. Our epidemiologic study did not examine patient outcomes and, therefore, only indirectly addresses the potential causes of treatment failure with azole antifungals. Although the VIPcheck is not 100% sensitive, assuming even a 5% pretest probability of azole resistance, the negative predictive value of the VIPcheck remains excellent at 99.9%, which gives us confidence in our estimate. Our results are thus informative regarding the risk of antifungal resistance across a large geographical area and suggest that the rate of azole antifungal resistance among *Aspergillus* species is low in the province of Québec.

ACKNOWLEDGMENTS

M.P.C. was supported by a postdoctoral training grant from Fonds de Recherche Québec Santé (FRQS). D.C.S. was supported by a Research Chair from the FRQS. VIPcheck plates were provided through a research grant by Gilead to O.A.C.

M.P.C., A.L., T.C.L., P.J.D., D.S., and D.C.S. have no conflicts of interest to disclose. P.E.V. reports research grants from Merck/MSD and F2G; is a consultant to Amplyx, Cidara, and F2G; and received lecture honoraria from Pfizer, Gilead Sciences, F2G and Merck/MSD. O.A.C. reports research grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Medicines Company, Medpace, Melinta Therapeutics, Merck/MSD, Pfizer, and Scynexis; is a consultant to Actelion, Allegra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, F2G, Gilead, IQVIA, Matinas, Medpace, Menarini Ricerche, Merck/MSD, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetrphase, and Vical; and received lecture honoraria from Astellas, Basilea, Gilead, Merck/MSD and Pfizer.

REFERENCES

- Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM. 2010. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). *Clin Infect Dis* 50:1101–1111. <https://doi.org/10.1086/651262>.
- Singh N, Paterson DL. 2005. *Aspergillus* infections in transplant recipients.

- ents. *Clin Microbiol Rev* 18:44–69. <https://doi.org/10.1128/CMR.18.1.44-69.2005>.
3. Taccone F, Van den Abeele A-M, Bulpa P, Misset B, Meersseman W, Cardoso T, Paiva J-A, Blasco-Navalpotro M, De Laere E, Dimopoulos G, Rello J, Vogelaers D, Blot SI. 2015. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. *Crit Care* 19:7. <https://doi.org/10.1186/s13054-014-0722-7>.
 4. Dufresne SF, Cole DC, Denning DW, Sheppard DC. 2017. Serious fungal infections in Canada. *Eur J Clin Microbiol Infect Dis* 36:987–992. <https://doi.org/10.1007/s10096-017-2922-y>.
 5. Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P, Che D, Dromer F. 2014. Population-based analysis of invasive fungal infections, France, 2001–2010. *Emerg Infect Dis* 20:1149–1155. <https://doi.org/10.3201/eid2007.140087>.
 6. Slobbe L, Polinder S, Doorduyn JK, Lugtenburg PJ, el Barzouhi A, Steyerberg EW, Rijnders BJA. 2008. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia–myelodysplastic syndrome treated with intensive chemotherapy: an observational study. *Clin Infect Dis* 47:1507–1512. <https://doi.org/10.1086/591531>.
 7. Steinmann J, Hamprecht A, Vehreschild MJGT, Cornely OA, Buchheidt D, Spiess B, Koldehoff M, Buer J, Meis JF, Rath P-M. 2015. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. *J Antimicrob Chemother* 70:1522–1526. <https://doi.org/10.1093/jac/dku566>.
 8. van der Linden JWM, Arendrup MC, Warris A, Lagrou K, Pelloux H, Hauser PM, Chryssanthou E, Mellado E, Kidd SE, Tortorano AM, Dannaoui E, Gaustad P, Baddley JW, Uekötter A, Lass-Flörl C, Klimko N, Moore CB, Denning DW, Pasqualotto AC, Kibbler C, Arikan-Akdagli S, Andes D, Meletiadis J, Naumiuk L, Nucci M, Melchers WJG, Verweij PE. 2015. Prospective multicenter international surveillance of azole resistance in *Aspergillus fumigatus*. *Emerg Infect Dis* 21:1041–1044. <https://doi.org/10.3201/eid2106.140717>.
 9. Lestrade P, Bentvelsen RG, Schauwvlieghe AFAD, Schalekamp S, van der Velden WJFM, Kuiper EJ, van Paassen J, van der Hoven B, van der Lee HA, Melchers WJG, de Haan AF, van der Hoeven HL, Rijnders BJA, van der Beek MT, Verweij PE. 2018. Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study. *Clin Infect Dis* <https://doi.org/10.1093/cid/ciy859>.
 10. Mortensen KL, Mellado E, Lass-Flörl C, Rodriguez-Tudela JL, Johansen HK, Arendrup MC. 2010. Environmental study of azole-resistant *Aspergillus fumigatus* and other aspergilli in Austria, Denmark, and Spain. *Antimicrob Agents Chemother* 54:4545–4549. <https://doi.org/10.1128/AAC.00692-10>.
 11. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. 2012. Isolation of multiple-triazole-resistant *Aspergillus fumigatus* strains carrying the TR/L98H mutations in the *cyp51A* gene in India. *J Antimicrob Chemother* 67:362–366. <https://doi.org/10.1093/jac/dkr443>.
 12. Liu M, Zeng R, Zhang L, Li D, Lv G, Shen Y, Zheng H, Zhang Q, Zhao J, Zheng N, Liu W. 2015. Multiple *cyp51A*-based mechanisms identified in azole-resistant isolates of *Aspergillus fumigatus* from China. *Antimicrob Agents Chemother* 59:4321–4325. <https://doi.org/10.1128/AAC.00003-15>.
 13. Wiederhold NP, Gil VG, Gutierrez F, Lindner JR, Albataineh MT, McCarthy DI, Sanders C, Fan H, Fothergill AW, Sutton DA. 2016. First detection of TR34 L98H and TR46 Y121F T289A *Cyp51* mutations in *Aspergillus fumigatus* isolates in the United States. *J Clin Microbiol* 54:168–171. <https://doi.org/10.1128/JCM.02478-15>.
 14. Buil JB, van der Lee HAL, Rijs AJMM, Zoll J, Hovestadt JAMF, Melchers WJG, Verweij PE. 2017. Single-center evaluation of an agar-based screening for azole resistance in *Aspergillus fumigatus* by using VIPcheck. *Antimicrob Agents Chemother* 61:e01250-17. <https://doi.org/10.1128/AAC.01250-17>.
 15. Clinical and Laboratory Standards Institute. 2017. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. CLSI document M38, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
 16. Clinical and Laboratory Standards Institute. 2017. Performance standards for antifungal susceptibility testing of filamentous fungi. CLSI document M61, 1st ed. Clinical and Laboratory Standards Institute, Wayne, PA.
 17. Clinical and Laboratory Standards Institute. 2018. Epidemiological cutoff values for antifungal susceptibility testing. CLSI supplement M59, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
 18. Cheng MP, Orejas JL, Arbona-Haddad E, Marty FM, Koo S, Hammond S. 2018. Comparison of voriconazole (VORI), isavuconazole (ISAV), and posaconazole (POSA) in the initial treatment of patients with invasive aspergillosis (IA). *Open Forum Infect Dis* 5:S140–S141. <https://doi.org/10.1093/ofid/ofy210.369>.